Greenblatt D J, Comer W H, Elliott H W, Shader R I, Knowles J A, Ruelius H W
J Clin Pharmacol. 1977 Aug-Sep;17(8-9):490-4. doi: 10.1002/j.1552-4604.1977.tb05641.x.
Four healthy male volunteers received 5 mg lorazepam as a single intravenous injection. Concentrations of lorazepam and its glucuronide metabolite were determined in multiple venous blood samples drawn during the 48 hours after dosing and in all urine collected during 96 hours after the dose. Mean pharmacokinetic parameters for lorazepam were: apparent elimination half-life, 13.2 hours; volume of distribution, 0.84 liter/kg; total clearance, 55.3 ml/min. Lorazepam glucuronide, the major metabolic product of lorazepam, promptly appeared in blood, reached peak levels within 6 hours of the dose, then declined in parallel with the parent compound. A mean of 69 per cent of the dose was recovered in urine as lorazepam glucuronide.
四名健康男性志愿者接受了5毫克劳拉西泮的单次静脉注射。在给药后48小时内采集的多个静脉血样以及给药后96小时内收集的所有尿液中测定了劳拉西泮及其葡萄糖醛酸代谢物的浓度。劳拉西泮的平均药代动力学参数为:表观消除半衰期13.2小时;分布容积0.84升/千克;总清除率55.3毫升/分钟。劳拉西泮的主要代谢产物劳拉西泮葡萄糖醛酸迅速出现在血液中,在给药后6小时内达到峰值水平,然后与母体化合物平行下降。平均69%的剂量以劳拉西泮葡萄糖醛酸的形式在尿液中回收。